Please assess the completion status of the following clinical trial:

Trial Title: A Type 2 Diabetes Study of the Longer-Term Glycemic Effect of AVANDAMET vs. Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The subject provides written informed consent.~* The subject is male or female and 18 to 75 years of age at the time of pre-screening.~* The subject has an established clinical diagnosis of type 2 diabetes according to recommended guidelines (e.g., American Diabetes Association, International Diabetes Federation, World Health Organization, Canadian Diabetes Association, or American Association of Clinical Endocrinologists).~* The subject is currently treated with diet and exercise, and has not taken more than 2 weeks of an anti-diabetic monotherapy or insulin in the past 6 months.~* The subject has a BMI \>25 kg/m2 at pre-screening.~* The subject has a Quest HbA1c 7.5% to 10.5% at pre-screening.~* The subject has a fasting capillary blood glucose 126 mg/dL (7mmol/L), as measured by the site staff at week 0.~* If the subject is a pre-menopausal female of child-bearing potential, she agrees to practice acceptable contraceptive measures (e.g. oral birth control pills, Norplant, Depo-Provera, an intrauterine device (IUD), a diaphragm with spermicide or a condom with spermicide, or abstinence) at least 1 month before screening, during the study, and for 30 days after the last dose of study medication is taken~* The subject is able and willing to perform self-monitoring of blood glucose as specified in this protocol.~Exclusion Criteria:~* The subject has taken an oral anti-diabetic monotherapy or insulin for more than 14 days in the past 6 months.~* The subject has presence of clinically significant renal or hepatic disease (serum creatinine 1.5 mg/dL (132.6 mol/L) for males and 1.4 mg/dL (123.8 mol/L) for females): ALT, AST, total bilirubin, or alkaline phosphatase \>2.5 times the upper limit of the normal (ULN) reference range.~* The subject has anemia defined by hemoglobin concentration \<11g/dL (110g/L) for males or \<10g/dL (100g/L) for females.~* Presence of unstable or severe angina, coronary insufficiency or New York Heart Association (NYHA) class III-IV or any congestive heart failure requiring pharmacologic treatment.~* The subject has systolic blood pressure \>160 mmHg or diastolic blood pressure \>90 mmHg~* The subject has a chronic disease requiring intermittent or chronic treatment with oral, intravenous, or intra-articular corticosteroids (i.e., only use of topical, inhaled or nasal corticosteroids is permitted).~* The subject has acute or chronic metabolic acidosis or a history of diabetic ketoacidosis.~* The subject has a clinically significant abnormality which in the judgment of the investigator makes the subject unsuitable for inclusion in the study (e.g., physical examination, laboratory tests, or electrocardiogram, etc).~* The subject has used an investigational agent within 30 days or 5 half-lives (whichever was longer) prior to pre-screening.~* The subject is a female who is lactating, pregnant, or planned to become pregnant.~* The subject has a prior history of severe edema or a medically serious fluid related event (e.g., heart failure).~* The subject has a history of macular edema.~* The subject has significant hypersensitivity (e.g., difficulty swallowing, difficulty breathing, and tachycardia or skin reaction) to TZDs, biguanides, or compounds with similar chemical structures.~* The subject has a diagnosis of cancer (other than squamous, basal cell, or cervical cancer in-situ) in the past 3 years and is receiving treatment for cancer.~* The subject has a history or suspicion of drug abuse or alcohol abuse within the last 6 months.~* The subject is known to have severe lactose intolerance.~* The subject is not willing to comply with visits and procedures described in the protocol.~* The subject has a disease that may affect bone turnover including, but not limited to: Paget's disease, hypercalcemia, hypocalcemia, hyperparathyroidism, hyperthyroidism, osteomalacia, metastatic bone disease~* The subject has a weight of greater than 300 lbs (136.4 kg).~* The subject has received treatment with bisphosphonates (≥1 month cumulative treatment within the last 12 months) or fluoride (dose greater than 10mg/day within the previous 5 years).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Metformin (Type: PLACEBO_COMPARATOR): MET began at a total daily dose of 500 mg and could be increased up to a maximum dose of MET 2000 mg. The dose level was to be increased unless a tolerability issue existed at the current dose level.
- Avandamet (Rosiglitazone maleate/metformin hydrochloride) (Type: ACTIVE_COMPARATOR): AVM began at a total daily dose of 4 mg/500 mg and could be increased up to a maximum dose of AVM 8 mg/2000 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).